Maha Reda Farhat, M.D., M.D.,C.M.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mycobacterium tuberculosis | 31 | 2024 | 1825 | 7.620 |
Why?
|
Tuberculosis, Multidrug-Resistant | 17 | 2024 | 910 | 5.980 |
Why?
|
Tuberculosis | 18 | 2024 | 1904 | 3.170 |
Why?
|
Antitubercular Agents | 20 | 2024 | 1319 | 3.020 |
Why?
|
Drug Resistance, Bacterial | 8 | 2022 | 1032 | 1.910 |
Why?
|
Microbial Sensitivity Tests | 17 | 2024 | 1871 | 1.890 |
Why?
|
Genome, Bacterial | 10 | 2023 | 754 | 1.790 |
Why?
|
Rifampin | 5 | 2024 | 315 | 1.710 |
Why?
|
Fluoroquinolones | 3 | 2017 | 308 | 1.430 |
Why?
|
Drug Resistance, Multiple, Bacterial | 5 | 2021 | 563 | 1.330 |
Why?
|
Phylogeny | 10 | 2023 | 2797 | 1.270 |
Why?
|
Antibiotics, Antitubercular | 1 | 2022 | 104 | 0.780 |
Why?
|
Tuberculosis, Lymph Node | 1 | 2021 | 19 | 0.780 |
Why?
|
Nitroimidazoles | 1 | 2020 | 106 | 0.700 |
Why?
|
Rifabutin | 1 | 2019 | 52 | 0.690 |
Why?
|
Tuberculin Test | 3 | 2008 | 214 | 0.630 |
Why?
|
Tuberculosis, Pulmonary | 2 | 2022 | 810 | 0.630 |
Why?
|
Delayed Diagnosis | 1 | 2021 | 438 | 0.600 |
Why?
|
Molecular Typing | 1 | 2017 | 106 | 0.590 |
Why?
|
BCG Vaccine | 4 | 2022 | 367 | 0.540 |
Why?
|
Molecular Diagnostic Techniques | 3 | 2019 | 602 | 0.530 |
Why?
|
DNA Gyrase | 1 | 2016 | 82 | 0.520 |
Why?
|
Appendicitis | 1 | 2021 | 644 | 0.500 |
Why?
|
Drug Resistance, Microbial | 2 | 2018 | 860 | 0.500 |
Why?
|
Clostridium Infections | 1 | 2021 | 548 | 0.500 |
Why?
|
Computational Biology | 4 | 2021 | 3518 | 0.490 |
Why?
|
Mutation | 16 | 2023 | 29717 | 0.480 |
Why?
|
Software | 5 | 2022 | 4434 | 0.480 |
Why?
|
Respiratory Muscles | 1 | 2013 | 140 | 0.440 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1071 | 0.410 |
Why?
|
Adjuvants, Immunologic | 2 | 2007 | 1000 | 0.400 |
Why?
|
Isoniazid | 3 | 2024 | 273 | 0.400 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2021 | 15494 | 0.400 |
Why?
|
Clofazimine | 2 | 2021 | 33 | 0.390 |
Why?
|
Genomics | 6 | 2024 | 5692 | 0.380 |
Why?
|
Virulence | 3 | 2023 | 1328 | 0.380 |
Why?
|
Respiration Disorders | 1 | 2013 | 370 | 0.360 |
Why?
|
Immunity, Innate | 1 | 2021 | 2956 | 0.330 |
Why?
|
Selection, Genetic | 1 | 2013 | 914 | 0.320 |
Why?
|
Anti-Bacterial Agents | 5 | 2022 | 7153 | 0.320 |
Why?
|
India | 3 | 2023 | 2187 | 0.310 |
Why?
|
Sputum | 2 | 2021 | 474 | 0.310 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 1 | 2013 | 520 | 0.310 |
Why?
|
Epistasis, Genetic | 2 | 2021 | 365 | 0.300 |
Why?
|
Sequence Analysis, DNA | 4 | 2022 | 4801 | 0.290 |
Why?
|
Humans | 47 | 2024 | 742088 | 0.260 |
Why?
|
Ethambutol | 2 | 2022 | 60 | 0.250 |
Why?
|
Models, Statistical | 2 | 2019 | 5100 | 0.250 |
Why?
|
Ethionamide | 1 | 2024 | 11 | 0.240 |
Why?
|
Genes, Bacterial | 2 | 2017 | 1078 | 0.220 |
Why?
|
Databases, Genetic | 2 | 2021 | 1780 | 0.220 |
Why?
|
ROC Curve | 2 | 2021 | 3528 | 0.210 |
Why?
|
Mycobacterium bovis | 1 | 2022 | 150 | 0.210 |
Why?
|
Amikacin | 1 | 2021 | 48 | 0.210 |
Why?
|
Kanamycin | 1 | 2021 | 64 | 0.200 |
Why?
|
Phylogeography | 1 | 2021 | 81 | 0.200 |
Why?
|
Evolution, Molecular | 2 | 2021 | 1937 | 0.200 |
Why?
|
Genetic Predisposition to Disease | 2 | 2021 | 17400 | 0.190 |
Why?
|
DNA Barcoding, Taxonomic | 1 | 2021 | 136 | 0.190 |
Why?
|
Stenotrophomonas maltophilia | 1 | 2020 | 16 | 0.190 |
Why?
|
Cholecystitis | 1 | 2020 | 182 | 0.170 |
Why?
|
Oxazoles | 1 | 2020 | 189 | 0.170 |
Why?
|
Cluster Analysis | 4 | 2020 | 2713 | 0.170 |
Why?
|
Community-Acquired Infections | 1 | 2023 | 463 | 0.170 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2020 | 403 | 0.170 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 1 | 2019 | 92 | 0.160 |
Why?
|
Bacterial Typing Techniques | 1 | 2019 | 256 | 0.160 |
Why?
|
Drug Tolerance | 1 | 2020 | 375 | 0.160 |
Why?
|
Genome-Wide Association Study | 4 | 2021 | 12220 | 0.160 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2020 | 232 | 0.160 |
Why?
|
DNA, Bacterial | 2 | 2022 | 1465 | 0.160 |
Why?
|
Private Sector | 1 | 2021 | 390 | 0.160 |
Why?
|
Reproducibility of Results | 4 | 2021 | 19862 | 0.150 |
Why?
|
Retrospective Studies | 8 | 2023 | 77098 | 0.150 |
Why?
|
Hospital Mortality | 3 | 2023 | 5310 | 0.150 |
Why?
|
Genome, Viral | 1 | 2020 | 667 | 0.140 |
Why?
|
Bacterial Proteins | 3 | 2019 | 3843 | 0.140 |
Why?
|
Workflow | 1 | 2021 | 846 | 0.140 |
Why?
|
Adaptation, Physiological | 1 | 2023 | 1310 | 0.140 |
Why?
|
Insurance Claim Review | 1 | 2021 | 720 | 0.140 |
Why?
|
Neisseria gonorrhoeae | 1 | 2018 | 238 | 0.140 |
Why?
|
Peru | 1 | 2019 | 881 | 0.140 |
Why?
|
Bacteremia | 1 | 2023 | 962 | 0.140 |
Why?
|
Genetics, Population | 1 | 2021 | 933 | 0.130 |
Why?
|
Gastrointestinal Diseases | 2 | 2021 | 1167 | 0.130 |
Why?
|
Benchmarking | 1 | 2022 | 1038 | 0.130 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2016 | 224 | 0.130 |
Why?
|
Ofloxacin | 1 | 2015 | 65 | 0.130 |
Why?
|
Qualitative Research | 1 | 2023 | 2680 | 0.130 |
Why?
|
Medical Record Linkage | 1 | 2016 | 284 | 0.130 |
Why?
|
Treatment Failure | 1 | 2021 | 2615 | 0.130 |
Why?
|
Genetic Variation | 2 | 2020 | 6540 | 0.120 |
Why?
|
Middle Aged | 10 | 2022 | 213127 | 0.120 |
Why?
|
Genotype | 4 | 2024 | 12946 | 0.110 |
Why?
|
Female | 12 | 2023 | 379592 | 0.110 |
Why?
|
Recurrence | 2 | 2022 | 8333 | 0.110 |
Why?
|
Ciprofloxacin | 1 | 2015 | 314 | 0.110 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2022 | 3585 | 0.110 |
Why?
|
Bayes Theorem | 1 | 2021 | 2303 | 0.110 |
Why?
|
Genetic Loci | 2 | 2019 | 2572 | 0.110 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 24913 | 0.100 |
Why?
|
Male | 11 | 2023 | 349538 | 0.100 |
Why?
|
Regression Analysis | 1 | 2021 | 6452 | 0.100 |
Why?
|
Manometry | 1 | 2013 | 444 | 0.100 |
Why?
|
Immunity, Cellular | 1 | 2017 | 1606 | 0.100 |
Why?
|
Diagnostic Tests, Routine | 1 | 2016 | 783 | 0.090 |
Why?
|
DNA Mutational Analysis | 1 | 2019 | 4187 | 0.090 |
Why?
|
Young Adult | 3 | 2022 | 56350 | 0.090 |
Why?
|
Mycolic Acids | 1 | 2009 | 54 | 0.090 |
Why?
|
Treatment Outcome | 5 | 2021 | 62966 | 0.090 |
Why?
|
Multivariate Analysis | 2 | 2021 | 12242 | 0.090 |
Why?
|
Insurance, Health | 1 | 2021 | 2493 | 0.080 |
Why?
|
Respiratory Function Tests | 1 | 2013 | 1613 | 0.080 |
Why?
|
Renal Replacement Therapy | 1 | 2011 | 258 | 0.080 |
Why?
|
Intraoperative Complications | 1 | 2015 | 1188 | 0.080 |
Why?
|
Adolescent | 3 | 2022 | 85649 | 0.080 |
Why?
|
Aged | 7 | 2022 | 162944 | 0.080 |
Why?
|
Electromyography | 1 | 2013 | 1391 | 0.080 |
Why?
|
Adult | 7 | 2022 | 213712 | 0.080 |
Why?
|
Promoter Regions, Genetic | 1 | 2019 | 5867 | 0.080 |
Why?
|
Cyclophosphamide | 1 | 2013 | 2236 | 0.070 |
Why?
|
Esophagus | 1 | 2013 | 1017 | 0.070 |
Why?
|
Aged, 80 and over | 3 | 2022 | 57683 | 0.070 |
Why?
|
Alleles | 2 | 2020 | 6931 | 0.070 |
Why?
|
Child | 3 | 2022 | 77478 | 0.070 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5304 | 0.070 |
Why?
|
Dyspnea | 1 | 2013 | 1298 | 0.060 |
Why?
|
Proteomics | 1 | 2018 | 3618 | 0.060 |
Why?
|
United States | 3 | 2021 | 69693 | 0.060 |
Why?
|
Acute Kidney Injury | 2 | 2021 | 1967 | 0.060 |
Why?
|
False Positive Reactions | 1 | 2006 | 981 | 0.060 |
Why?
|
Critical Care | 2 | 2021 | 2640 | 0.060 |
Why?
|
DNA Repair | 1 | 2013 | 2042 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2022 | 5724 | 0.060 |
Why?
|
Surgical Procedures, Operative | 1 | 2015 | 1873 | 0.060 |
Why?
|
Gene Expression Regulation, Bacterial | 1 | 2009 | 1119 | 0.060 |
Why?
|
Incidence | 1 | 2021 | 20928 | 0.050 |
Why?
|
Phenotype | 4 | 2024 | 16331 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 10943 | 0.050 |
Why?
|
Prevalence | 1 | 2019 | 15194 | 0.050 |
Why?
|
Prognosis | 2 | 2019 | 29010 | 0.050 |
Why?
|
Locus Control Region | 1 | 2020 | 20 | 0.050 |
Why?
|
Risk Factors | 3 | 2023 | 72145 | 0.050 |
Why?
|
Prone Position | 1 | 2021 | 194 | 0.050 |
Why?
|
Neuromuscular Blockade | 1 | 2021 | 146 | 0.040 |
Why?
|
Pressure Ulcer | 1 | 2021 | 154 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2016 | 4440 | 0.040 |
Why?
|
Creatine Kinase | 1 | 2021 | 694 | 0.040 |
Why?
|
Shock | 1 | 2021 | 318 | 0.040 |
Why?
|
Pyrazinamide | 1 | 2018 | 54 | 0.040 |
Why?
|
Child, Preschool | 1 | 2021 | 40955 | 0.040 |
Why?
|
Pneumonia, Bacterial | 1 | 2021 | 316 | 0.040 |
Why?
|
Critical Illness | 2 | 2021 | 2665 | 0.040 |
Why?
|
Decision Support Techniques | 1 | 2008 | 1952 | 0.040 |
Why?
|
Boston | 2 | 2021 | 9305 | 0.040 |
Why?
|
Geography | 1 | 2020 | 669 | 0.040 |
Why?
|
Hydroxychloroquine | 1 | 2021 | 408 | 0.040 |
Why?
|
Molecular Epidemiology | 1 | 2019 | 468 | 0.040 |
Why?
|
Opportunistic Infections | 1 | 2020 | 389 | 0.040 |
Why?
|
Disease Progression | 1 | 2013 | 13256 | 0.040 |
Why?
|
World Health Organization | 1 | 2022 | 1317 | 0.030 |
Why?
|
Drug Resistance | 1 | 2022 | 1608 | 0.030 |
Why?
|
Steroids | 1 | 2021 | 931 | 0.030 |
Why?
|
Oxidoreductases | 1 | 2018 | 424 | 0.030 |
Why?
|
Thromboembolism | 1 | 2021 | 983 | 0.030 |
Why?
|
Gonorrhea | 1 | 2018 | 335 | 0.030 |
Why?
|
Antimalarials | 1 | 2021 | 903 | 0.030 |
Why?
|
Propensity Score | 1 | 2020 | 1771 | 0.030 |
Why?
|
Gene Expression Profiling | 1 | 2009 | 9410 | 0.030 |
Why?
|
Access to Information | 1 | 2016 | 320 | 0.030 |
Why?
|
Bacteria | 1 | 2023 | 2102 | 0.030 |
Why?
|
Antibodies, Bacterial | 1 | 2018 | 1469 | 0.030 |
Why?
|
Respiration, Artificial | 1 | 2023 | 2566 | 0.030 |
Why?
|
Emergency Treatment | 1 | 2015 | 517 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2006 | 12958 | 0.020 |
Why?
|
Disease Outbreaks | 1 | 2020 | 1768 | 0.020 |
Why?
|
Cross Infection | 1 | 2020 | 1413 | 0.020 |
Why?
|
Genetic Markers | 1 | 2017 | 2633 | 0.020 |
Why?
|
Information Storage and Retrieval | 1 | 2016 | 824 | 0.020 |
Why?
|
Protein Conformation | 1 | 2018 | 4013 | 0.020 |
Why?
|
Epidemics | 1 | 2016 | 521 | 0.020 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2021 | 1348 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6534 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2015 | 2885 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2023 | 3679 | 0.020 |
Why?
|
Hospital Costs | 1 | 2015 | 980 | 0.020 |
Why?
|
Length of Stay | 1 | 2021 | 6294 | 0.020 |
Why?
|
Forecasting | 1 | 2016 | 2948 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2016 | 15056 | 0.020 |
Why?
|
Survival Rate | 1 | 2021 | 12773 | 0.020 |
Why?
|
Comorbidity | 1 | 2021 | 10372 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2013 | 35342 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2018 | 13814 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2018 | 5095 | 0.020 |
Why?
|
Metabolic Networks and Pathways | 1 | 2009 | 782 | 0.020 |
Why?
|
Age Factors | 1 | 2021 | 18355 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8328 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7276 | 0.010 |
Why?
|
Time Factors | 2 | 2016 | 40054 | 0.010 |
Why?
|
Fatty Acids | 1 | 2009 | 1806 | 0.010 |
Why?
|
Risk Assessment | 2 | 2015 | 23320 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13403 | 0.010 |
Why?
|
Databases, Factual | 1 | 2015 | 7716 | 0.010 |
Why?
|
Cohort Studies | 1 | 2023 | 40450 | 0.010 |
Why?
|
Algorithms | 2 | 2009 | 13853 | 0.010 |
Why?
|
Survival Analysis | 1 | 2011 | 10248 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 53187 | 0.010 |
Why?
|
Internet | 1 | 2008 | 3062 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2011 | 9941 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2015 | 15244 | 0.010 |
Why?
|
Models, Biological | 1 | 2009 | 9581 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2009 | 12071 | 0.010 |
Why?
|
Animals | 1 | 2013 | 168561 | 0.000 |
Why?
|